Pathological Examination Market

SKU: DMBT5772 | Last Updated On: Oct 26 2022 | Available Formats

Pathological Examination Market Expected to reach at a high CAGR of 9.9% by 2029

Pathological Examination Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 9.9 % during the forecast period (2022-2029). Pathological examination is a multi-step process essential for diagnosing infections, genetic abnormalities, and neoplasms. The physician determines the course of treatment by reviewing the data obtained by the pathology examination, which is crucial in determining the existence or absence of cancer. It also contains information on how to choose the best treatment option.

As per DataM Intelligence, Pathological Examination Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Pathological Examination Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Pathological Examination Market in the United States and Canada produces the utmost share. Whereas the European Pathological Examination Market is projected to continue its presence globally during the period of 2022- 2029.

Pathological Examination Market Scope

Metrics

Details

Market CAGR

9.9%

Segments Covered

By Test, By Service, By Application, By End-user, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into Market, Get Our Sample Brochure

Market Dynamics

Technological advancements in Pathological Examination are expected to drive market growth.

Advances have been made in recent decades in many exciting fields, including image capture, data analysis and AI, and single-cell biomarker testing. Each of them has the potential to change the way cytopathology is practiced. At the intersections of these new tools, incredibly sophisticated information about individual patients' tumors is gleaned. These technologies can streamline workflows, reduce diagnostic test turnaround times to hours or less, find granular prognostic and predictive features to drive precision medicine, reduce costs and better utilize resources. Moreover, the successful implementation of digital pathology systems and AI is contingent on effective regulation, which is still in its infancy. The Food and Drug Administration (FDA) does not require permission to employ digital pathology systems in a clinical setting. Instead, laboratory-created tests are conceived, made, and validated in specific laboratories. The College of American Pathologists (CAP) requires that this be documented explicitly in the pathology report.

Additionally, Pharmaceutical dosage forms with an ingestible sensor inside the pill to send data after ingestion have been developed thanks to technological improvements. The pathological examination has allowed for monitoring patients' conditions, sending reminders to follow the prescribed treatment, and notification of healthcare status updates. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Lack of qualified and educated healthcare workers, a high cost of pathological investigation, a shortage of pathologists, a lack of compensation policy, and a high initial investment are some factors the market is expected to hamper in the forecast period.

Industry Analysis

The pathological examination market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, reimbursement scenario etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Since the outbreak, much has been learned about the COVID-19 pandemic's clinical course, prognostic inflammatory markers, sickness outcomes, and mechanical ventilation method. Three clinical phases have been developed based on viral infection, lung involvement with inflammation, and fibrosis. SARS-CoV-2 has also been discovered in the heart, liver, kidneys, gastrointestinal tract, spleen, lymph nodes, skin, and placenta, among other organs. On the other hand, pathological findings in these organs were frequently nonspecific. In the later phases of COVID-19, epithelial damage and a considerable inflammatory infiltration were found in the liver, kidneys, gastrointestinal system, and placenta, which could be linked to SARS-CoV-2 infection. As a result, the demand for pathological examination has skyrocketed.

In contrast, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Digital Pathology segment is expected to hold the largest market share in pathological examination market

The digital pathology segment is expected to dominate in 2021. The segment is benefited because the digital images are analyzed using a computer monitor or mobile device and a complete slide image scanner in digital pathology. It functions the same way as a regular light microscope, allowing pathologists to move slides around the same way. It has improved the efficiency of pathology labs and increased income. The labs deploy computationally enabled digital pathology powered by artificial intelligence to assist pathologists. Quantitative image analysis is available to integrate data into the lab information system. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global pathological examination market

In 2021, North America accounted for the highest revenue share. Increasing prevalence of stroke, cancer, technological advancement in the devices, favorable reimbursement policies, increasing research & development activities and enhancing healthcare infrastructure are some factors the market is expected to boost in the forecast period. For instance, according to the American Heart Association News, the number of young adults dying from stroke, particularly men, has risen over the past decade. There were 460,000 strokes in the United States in 2019 (two-thirds of which were ischemic), 190,000 stroke-related deaths, and 3.83 million stroke disability-adjusted life years. The prevalence of stroke in the general population increased by almost 60% between 1990 and 2019.

Moreover, stroke affects more than 795,000 people in the United States annually. The first or new strokes account for around 610,000 of these. A total of 185,000 strokes occur in people who have already had a stroke, accounting for approximately one-fourth of all strokes. Therefore, increasing prevalence has increased the demand for pathological examination in the region. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.  

Competitive Landscape

Major key players in the pathological examination market are 3DHISTECH Ltd., NeoGenomics Laboratories, Inc., F. Hoffmann-La Roche Ltd, Bio SB, Agilent Technologies, Inc., Quest Diagnostics Incorporated, Sonic Healthcare, Diapath S.p.A., BioGenex, Leica Biosystems                    

3DHISTECH Ltd.:

Overview:

3DHISTECH, founded in 1996, is the first European manufacturer of digital pathology devices and one of the global market leaders, with more than 1500 systems sold. It is dedicated to providing clinical pathologists, researchers and universities with digital pathology solutions to facilitate quick and accurate diagnostics, supporting medical discoveries and fostering education. The company is developing and manufacturing a wide range of PANNORAMIC whole slide scanners, Track & Sign and CaseManager laboratory and pathology management, CaseViewer digital microscopy and QuantCenter image analysis software solutions. Other products include tissue microarray machinery.

­Product Portfolio:

Pannoramic 250 FLASH III: 3DHISTECH Pannoramic 250 Flash III, a digital pathology research and storage all-in-one solution. With 60 slides per hour, enjoy greater speed and efficiency in ordinary digital pathology.

The global pathological examination market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest